Notes: DMHCA is a liver X receptor (LXR) agonist.{25539} It activates LXRα and LXRβ in CV-1 cells expressing the human receptors in reporter assays (EC50 = 2 µM for both). DMHCA also inhibits ∆24-dehydrocholesterol reductase (DHCR24; IC50 = 0.7 nM).{64110} It does not induce steatosis or increase liver triglyceride levels compared with the LXR agonist T0901317 (Item No. 71810) in mice when administered at a dose of 80 mg/kg.{69182} DMHCA (8 mg/kg) reduces the size of atherosclerotic lesions in ApoE-/- mice fed a Western diet. It decreases proteinuria and hepatic cholesterol levels in a mouse model of diabetic nephropathy induced by streptozotocin (Item No. 13104).{69183}